🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesDo the heart benefits go away if I stop taking it? — anyone have experience?

Do the heart benefits go away if I stop taking it? — anyone have experience?

LibrarianMeg Fri, Jan 16, 2026 at 2:10 PM 7 replies 975 viewsPage 1 of 2
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Jan 16, 2026 at 2:10 PM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

So the question, as narrowly as I can put it: how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

I would rather have one careful answer than five confident ones.

36 14Dr.NateNeph, PharmD_Rodriguez, julia.endo and 33 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jan 16, 2026 at 4:39 PM#2
LibrarianMeg said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Senior perspective on cardiovascular risk: I'm 68 years old and started this journey skeptically. My cardiologist recommended it after years of failed interventions.

14 months later: down 51 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Last edited: Jan 16, 2026 at 5:39 PM
37 15Dr.PulmRoch, maya_sedona, stefan_berlin and 34 others
Reply Quote Save Share Report
GraceAZ_72
Member
156
678
Jan 2025
Tucson, AZ
Jan 16, 2026 at 7:08 PM#3
BethLabQueen said:
Senior perspective on cardiovascular risk: I'm 68 years old and started this journey skeptically.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

38 16SallyK_inj, CryptoCarl, MariaRD and 35 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jan 16, 2026 at 9:37 PM#4
LibrarianMeg said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Same pattern here, and in the same order. Posting only so the count is not one.

39 17Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 36 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Jan 17, 2026 at 12:30 PM#5

Adding the clinical framing, because it changes how the question reads.

Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

40 18Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 37 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register